Eluxadoline

Eluxadoline

Clinical data
Trade names	Viberzi
Routes of administration	Oral
ATC code	A07DA06 (WHO)
Legal status
Legal status	US: Schedule IV
Pharmacokinetic data
Protein binding	81%
Biological half-life	3.7–6 hours
Excretion	82.2% (feces), <1% (urine)
Identifiers
IUPAC name 5-({[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
CAS Number	864821-90-9
PubChem (CID)	11250029
IUPHAR/BPS	7691
ChemSpider	9425062
UNII	45TPJ4MBQ1
KEGG	D10403
Chemical and physical data
Formula	C32H35N5O5
Molar mass	569.6508 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
InChI InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1 Key:QFNHIDANIVGXPE-FNZWTVRRSA-N

Eluxadoline (INN, USAN) (brand name Viberzi vye-BER-zee; former developmental code name JNJ-27018966) is an orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use by the United States Food and Drug Administration on May 27, 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.

This drug is contraindicated in case of having:

Common adverse effects in the two phase III clinical trials were constipation and nausea but rates of discontinuation due to constipation were low for both eluxadoline and placebo. Rare adverse effects: fatigue, bronchitis, viral gastroenteritis. Rare serious adverse effect in a clinical trial was pancreatitis with a general incidence of 0.3% - higher incidence with 100 mg dose (0.3%) than with 75 mg dose (0.2%).

Elevated concentrations of eluxadoline were observed with coadministraion of inhibitors of the transporter protein OATP1B1, such as:

Also, concurrent use of other drugs that cause constipation is not preferred, such as:

Eluxadoline increases the concentrations of drugs which are OATP1B1 and BCRP substrates. Also, coadministration of eluxadoline with rosuvastatin may increase the risk of rhabdomyolysis.

Eluxadoline is a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system.